Lexeo Therapeutics, Inc. Common Stock

NASDAQ:LXEO

Biotechnology

Healthcare
$2.95 -0.94%

-$0.05 today

Market cap
$244.23M
Beta
1.39
P/E (TTM)
-4.6
EPS (TTM)
-$1.08
52W Low $3.60High $10.99

Volume 1.76M

Average 0.86M

Income Statement

Follow revenue through to earnings.

Revenue

$0.00

FY 2025 · Annual

Operating Income

-$109.26M

FY 2025 · Annual

Net Income

-$99.96M

FY 2025 · Annual

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue1.66M654K000
Cost of Revenue00000
Gross Profit1.66M654K000
Gross Margin100.0%100.0%———
Research & Development45.12M49.16M53.13M74.09M63.8M
Selling, General & Admin7.17M12M15.38M31.68M45.46M
Operating Expenses52.29M61.16M68.51M105.77M109.26M
Depreciation & Amortization13K1.15M1.84M2M2.08M
EBITDA(50.61M)(58.04M)(64.35M)(96.19M)(97.68M)
EBITDA Margin-3054.3%-8874.8%———
Operating Income(50.64M)(60.51M)(68.51M)(105.77M)(109.26M)
Operating Margin-3055.9%-9252.1%———
Interest Income15K1.33M2.87M7.56M6.13M
Interest Expense091K205K114K206K
Other Income / Expenses15K1.23M2.12M7.43M9.3M
Income Before Tax(50.62M)(59.28M)(66.39M)(98.33M)(99.96M)
Pre-Tax Margin-3055.0%-9063.8%———
Income Tax Expense00000
Net Income(50.62M)(59.28M)(66.39M)(98.33M)(99.96M)
Net Margin-3055.0%-9063.8%———
EPS (Basic)(2.01)(2.36)(2.49)(3.09)(1.86)
EPS (Diluted)(2.01)(2.40)(2.49)(3.09)(1.86)
Weighted Avg Shares25.17M25.17M26.65M31.79M53.65M
Weighted Avg Shares (Diluted)25.17M25.17M26.65M31.79M53.65M

LXEO Earnings Waterfall · TTM

NASDAQ:LXEO · Revenue to Net Income

Key Ratios

EPS$-1.45
Gross Margin0.0%
Net Margin0.0%
P/E Ratio-5.4
P/S Ratio0.0

Analysis

$0 of revenue converted into -$87.5M of net income for the selected period. Gross margin is 0.0% and net margin is 0.0%, showing how much revenue survives after costs and taxes. EPS is $-1.45, tying the income statement back to per-share earnings.

Recent Filings

Recent regulatory filings

FilingDescriptionDate
SC 13G/ASC 13G/A filingNov 13, 2026
SC 13GSC 13G filingNov 10, 2026
EFFECTEFFECT filingNov 4, 2026
S-3S-3 filingOct 29, 2026
SC 13GSC 13G filingOct 13, 2026

How much revenue does LXEO generate?

Lexeo Therapeutics, Inc. Common Stock (LXEO) reported $0.00 of revenue in fiscal 2025.

Is LXEO profitable?

Lexeo Therapeutics, Inc. Common Stock (LXEO) reported -$99.96M of net income.